Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies.

ABSTRACT:

Background

Recent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed 'HER2-low' has been identified in tumors previously classified as 'HER2-negative'. Daily practice in pathology and medical oncology is expected to align to current recommendations, but patient access to novel anticancer drugs across geographies might be impeded due to local challenges.

Materials and methods

An expert meeting involving ten regional pathology and oncology opinion leaders experienced in BC management in four Central and Eastern Europe (CEE) countries (Bulgaria, Croatia, Serbia, Slovenia) was held. Herein we summarized the cu

SUBMITTER: Borstnar S 

PROVIDER: S-EPMC11165977 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature